Clinical Trial Update: BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating neoadjuvant low-dose stereotactic body radiotherapy combined with ipilimumab and nivolumab for non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Brown University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING